News Releases

Date Title and Summary
Toggle Summary electroCore Provides Select Third Quarter 2022 Financial Guidance
ROCKAWAY, N.J. , Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022.  Financial Guidance Preliminary unaudited financial
Toggle Summary electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devices ROCKAWAY, N.J. , Sept. 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and
Toggle Summary Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals
ROCKAWAY, N.J. , Sept. 20, 2022 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine company, today announced its plans to hold its fiscal year 2022 annual meeting of stockholders (the “2022 Annual Meeting”) on Friday, December 2, 2022 .
Toggle Summary gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder
ROCKAWAY, N.J. , Sept. 07, 2022 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript,  Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological
Toggle Summary electroCore to Participate at Upcoming Investor Conferences
ROCKAWAY, N.J. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger , will be participating at the H.C. Wainwright 24th Global Investment Conference and
Toggle Summary electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
ROCKAWAY, N.J. , Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger , will be presenting at the Canaccord Genuity 42nd Annual Growth Conference.
Toggle Summary electroCore Announces Record Second Quarter 2022 Financial Results
Record second quarter 2022 net sales of $2.2 million , increased 70% over second quarter 2021 and 14% sequentially Company to host a conference call and webcast today, August 4, 2022 at 4:30 pm EDT ROCKAWAY, N.J. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.
Toggle Summary electroCore to Announce Second Quarter 2022 Financial Results on August 4
ROCKAWAY, N.J. , July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the second quarter ended June 30, 2022 , after the close of the market on Thursday, August 4, 2022 .
Toggle Summary electroCore Provides Select Second Quarter 2022 Financial Guidance
Record   revenue will be at least $2.1 million ; approximately 65% growth over second quarter 2021 June 30, 2022 , cash and cash equivalents balance of approximately $26.6 million   ROCKAWAY, N.J. , July 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a
Toggle Summary electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome
ROCKAWAY, N.J. , July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS)